



CD283 Antibody [TLR3.7] (PE)

CATALOG NUMBER: 76-956

Specifications

SPECIES REACTIVITY:	Human
TESTED APPLICATIONS:	FACS
USER NOTE:	Optimal dilutions for each application to be determined by the researcher.
SPECIFICITY:	The TLR3.7 monoclonal antibody specifically reacts with human CD283 (TLR3), a type I transmembrane signaling receptor containing IL-1 receptor like intracellular domain and leucine-rich repeats (LRR) in the extracellular domain.
HOST SPECIES:	Mouse

Properties

PURIFICATION:	The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
PHYSICAL STATE:	liquid
BUFFER:	Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, pH7.2.
CONCENTRATION:	0.2 mg/mL
STORAGE CONDITIONS:	The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze.
CLONALITY:	Monoclonal
ISOTYPE:	Mouse IgG1, kappa
CONJUGATE:	PE

Additional Info

ALTERNATE NAMES:	CD283, IIAE2, TLR3
OFFICIAL SYMBOL:	TLR3
GENE ID:	7098

Background

BACKGROUND:	The TLR3.7 monoclonal antibody specifically reacts with human CD283 (TLR3), a type I transmembrane signaling receptor containing IL-1 receptor like intracellular domain and leucine-rich repeats (LRR) in the extracellular domain. It is expressed by dendritic cells and recognize double-stranded RNA and polyinosine-polycytidylic acid. Upon ligand binding, CD283 induces type I interferon production and activation of the nuclear factor kappa-light-chain-enhancer of activated B cells complex (NF-κB).
REFERENCES:	<p>1) Paterson, A. M., Brown, K. E., Keir, M. E., Vanguri, V. K., Riella, L. V., Chandraker, A., ... Sharpe, A. H. (2011). The programmed death-1 ligand 1: B7-1 pathway restrains diabetogenic effector T cells in vivo. <i>The Journal of Immunology</i>, 187(3), 1097-1105</p> <p>2) Koehn, B. H., Ford, M. L., Ferrer, I. R., Borom, K., Gangappa, S., Kirk, A. D., Larsen, C. P. (2008). PD-1-dependent mechanisms maintain peripheral tolerance of donor-reactive CD8+ T cells to transplanted tissue. <i>The Journal of Immunology</i>, 181(8), 5313-5322.</p> <p>3) Maier, H., Isogawa, M., Freeman, G. J., Chisari, F. V. (2007). PD-1: PD-L1 interactions contribute to the</p>

FOR RESEARCH USE ONLY

December 13, 2016